The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh

Lorna Guinness, Peter Vickerman, Zahidul Quayyum, Anna Foss, Charlotte Watts, Andrea Rodericks, Tasnim Azim, Smarajit Jana, Lilani Kumaranayake

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aims To assess the cost-effectiveness of the CARE-SHAKTI harm reduction intervention for injecting drug users (IDUs) over a 3-year period, the impact on the cost-effectiveness of stopping after 3 years and how the cost-effectiveness might vary with baseline human immunodeficiency virus (HIV) prevalence.

Design Economic cost data were collected from the study site and combined with impact estimates derived from a dynamic mathematical model.

Setting Dhaka, Bangladesh, where the HIV prevalence has remained low despite high-risk sexual and injecting behaviours, and growing HIV epidemics in neighbouring countries.

Findings The cost per HIV infection prevented over the first 3 years was US$110.4 (33.1–182.3). The incremental cost-effectiveness of continuing the intervention for a further year, relative to stopping at the end of year 3, is US$97 if behaviour returns to pre-intervention patterns. When baseline IDU HIV prevalence is increased to 40%, the number of HIV infections averted is halved for the 3-year period and the cost per HIV infection prevented doubles to US$228.

Conclusions The analysis confirms that harm reduction activities are cost-effective. Early intervention is more cost-effective than delaying activities, although this should not preclude later intervention. Starting harm reduction activities when IDU HIV prevalence reaches as high as 40% is still cost-effective. Continuing harm reduction activities once a project has matured is vital to sustaining its impact and cost-effectiveness.
Original languageEnglish
Pages (from-to)319-328
Number of pages10
JournalAddiction
Volume105
Issue number2
Early online date18 Nov 2009
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Harm Reduction
Bangladesh
Drug Users
Cost-Benefit Analysis
HIV
Costs and Cost Analysis
Virus Diseases
Sexual Behavior
Theoretical Models
Economics

Keywords

  • Bangladesh
  • cost-effectiveness
  • economics
  • HIV
  • injecting drug users

Cite this

Guinness, L., Vickerman, P., Quayyum, Z., Foss, A., Watts, C., Rodericks, A., ... Kumaranayake, L. (2010). The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. Addiction, 105(2), 319-328. https://doi.org/10.1111/j.1360-0443.2009.02755.x

The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. / Guinness, Lorna; Vickerman, Peter; Quayyum, Zahidul; Foss, Anna; Watts, Charlotte; Rodericks, Andrea; Azim, Tasnim; Jana, Smarajit; Kumaranayake, Lilani.

In: Addiction, Vol. 105, No. 2, 02.2010, p. 319-328.

Research output: Contribution to journalArticle

Guinness, L, Vickerman, P, Quayyum, Z, Foss, A, Watts, C, Rodericks, A, Azim, T, Jana, S & Kumaranayake, L 2010, 'The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh', Addiction, vol. 105, no. 2, pp. 319-328. https://doi.org/10.1111/j.1360-0443.2009.02755.x
Guinness, Lorna ; Vickerman, Peter ; Quayyum, Zahidul ; Foss, Anna ; Watts, Charlotte ; Rodericks, Andrea ; Azim, Tasnim ; Jana, Smarajit ; Kumaranayake, Lilani. / The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. In: Addiction. 2010 ; Vol. 105, No. 2. pp. 319-328.
@article{d4e885cd731f4fa9a2f9b842f34774e5,
title = "The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh",
abstract = "Aims To assess the cost-effectiveness of the CARE-SHAKTI harm reduction intervention for injecting drug users (IDUs) over a 3-year period, the impact on the cost-effectiveness of stopping after 3 years and how the cost-effectiveness might vary with baseline human immunodeficiency virus (HIV) prevalence. Design Economic cost data were collected from the study site and combined with impact estimates derived from a dynamic mathematical model. Setting Dhaka, Bangladesh, where the HIV prevalence has remained low despite high-risk sexual and injecting behaviours, and growing HIV epidemics in neighbouring countries. Findings The cost per HIV infection prevented over the first 3 years was US$110.4 (33.1–182.3). The incremental cost-effectiveness of continuing the intervention for a further year, relative to stopping at the end of year 3, is US$97 if behaviour returns to pre-intervention patterns. When baseline IDU HIV prevalence is increased to 40{\%}, the number of HIV infections averted is halved for the 3-year period and the cost per HIV infection prevented doubles to US$228. Conclusions The analysis confirms that harm reduction activities are cost-effective. Early intervention is more cost-effective than delaying activities, although this should not preclude later intervention. Starting harm reduction activities when IDU HIV prevalence reaches as high as 40{\%} is still cost-effective. Continuing harm reduction activities once a project has matured is vital to sustaining its impact and cost-effectiveness.",
keywords = "Bangladesh, cost-effectiveness, economics, HIV, injecting drug users",
author = "Lorna Guinness and Peter Vickerman and Zahidul Quayyum and Anna Foss and Charlotte Watts and Andrea Rodericks and Tasnim Azim and Smarajit Jana and Lilani Kumaranayake",
year = "2010",
month = "2",
doi = "10.1111/j.1360-0443.2009.02755.x",
language = "English",
volume = "105",
pages = "319--328",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh

AU - Guinness, Lorna

AU - Vickerman, Peter

AU - Quayyum, Zahidul

AU - Foss, Anna

AU - Watts, Charlotte

AU - Rodericks, Andrea

AU - Azim, Tasnim

AU - Jana, Smarajit

AU - Kumaranayake, Lilani

PY - 2010/2

Y1 - 2010/2

N2 - Aims To assess the cost-effectiveness of the CARE-SHAKTI harm reduction intervention for injecting drug users (IDUs) over a 3-year period, the impact on the cost-effectiveness of stopping after 3 years and how the cost-effectiveness might vary with baseline human immunodeficiency virus (HIV) prevalence. Design Economic cost data were collected from the study site and combined with impact estimates derived from a dynamic mathematical model. Setting Dhaka, Bangladesh, where the HIV prevalence has remained low despite high-risk sexual and injecting behaviours, and growing HIV epidemics in neighbouring countries. Findings The cost per HIV infection prevented over the first 3 years was US$110.4 (33.1–182.3). The incremental cost-effectiveness of continuing the intervention for a further year, relative to stopping at the end of year 3, is US$97 if behaviour returns to pre-intervention patterns. When baseline IDU HIV prevalence is increased to 40%, the number of HIV infections averted is halved for the 3-year period and the cost per HIV infection prevented doubles to US$228. Conclusions The analysis confirms that harm reduction activities are cost-effective. Early intervention is more cost-effective than delaying activities, although this should not preclude later intervention. Starting harm reduction activities when IDU HIV prevalence reaches as high as 40% is still cost-effective. Continuing harm reduction activities once a project has matured is vital to sustaining its impact and cost-effectiveness.

AB - Aims To assess the cost-effectiveness of the CARE-SHAKTI harm reduction intervention for injecting drug users (IDUs) over a 3-year period, the impact on the cost-effectiveness of stopping after 3 years and how the cost-effectiveness might vary with baseline human immunodeficiency virus (HIV) prevalence. Design Economic cost data were collected from the study site and combined with impact estimates derived from a dynamic mathematical model. Setting Dhaka, Bangladesh, where the HIV prevalence has remained low despite high-risk sexual and injecting behaviours, and growing HIV epidemics in neighbouring countries. Findings The cost per HIV infection prevented over the first 3 years was US$110.4 (33.1–182.3). The incremental cost-effectiveness of continuing the intervention for a further year, relative to stopping at the end of year 3, is US$97 if behaviour returns to pre-intervention patterns. When baseline IDU HIV prevalence is increased to 40%, the number of HIV infections averted is halved for the 3-year period and the cost per HIV infection prevented doubles to US$228. Conclusions The analysis confirms that harm reduction activities are cost-effective. Early intervention is more cost-effective than delaying activities, although this should not preclude later intervention. Starting harm reduction activities when IDU HIV prevalence reaches as high as 40% is still cost-effective. Continuing harm reduction activities once a project has matured is vital to sustaining its impact and cost-effectiveness.

KW - Bangladesh

KW - cost-effectiveness

KW - economics

KW - HIV

KW - injecting drug users

U2 - 10.1111/j.1360-0443.2009.02755.x

DO - 10.1111/j.1360-0443.2009.02755.x

M3 - Article

VL - 105

SP - 319

EP - 328

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - 2

ER -